NCT00223054
Completed
Not Applicable
Polymorphism of the Cytochrome P450-system and the MDR-system in Renal Transplants Receiving the Immunosuppressive Drugs Tacrolimus, Sirolimus, Everolimus or Cyclosporine A
University Hospital Schleswig-Holstein1 site in 1 country200 target enrollmentMarch 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Function of Renal Transplant
- Sponsor
- University Hospital Schleswig-Holstein
- Enrollment
- 200
- Locations
- 1
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
In this study the researchers want to investigate genetic polymorphisms of cytochrome 450 enzymes and the multiple drug resistance (MDR) gene in renal transplant patients to look for differences in dosing of immunosuppressive drugs (tacrolimus, sirolimus, everolimus, cyclosporine A).
All patients who receive one of these drugs can be included and drug blood trough levels, dosing and genetics are compared.
Detailed Description
Primary endpoint is the 1. serum creatinine in patients with and without polymorphysms 2. rate of rejections in patients with and without polymorphysms
Investigators
Eligibility Criteria
Inclusion Criteria
- •Renal transplant patients receiving one or more of the following drugs:
- •tacrolimus
- •sirolimus
- •everolimus
- •cyclosporin A
- •fluvastatin
- •Informed consent given by the patient
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Genetic Variability in CYP2D6 in U.S Active Duty PopulationPharmacologic ActionNCT02960568Walter Reed Army Institute of Research (WRAIR)550
Recruiting
Not Applicable
Creation of cytochrome P450 genotyping panel./AJPRN-UMIN000041697SOUSEIKAI Fukuoka Mirai Hospital4,000
Completed
Not Applicable
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With PsychosisSchizophreniaSchizoaffective DisorderPsychotic Disorder Not Otherwise SpecifiedSevere Bipolar Disorder With Psychotic FeaturesNCT01878513Northwell Health88
Completed
Phase 1
Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its MetabolitesCytochrome P450 CYP3A5 Enzyme PolymorphismHealthy SubjectsPharmacokinetics of MaravirocNCT01980329Johns Hopkins University24
Completed
Not Applicable
Influence of cytochrome P450 phenotypes on changes of drug-induced these enzyme activitiesHealthy volunteerJPRN-UMIN000016113Hamamatsu University School of Medicine20